RANDOM PROSPECTIVE-STUDY OF VINDESINE VERSUS VINDESINE PLUS HIGH-DOSE CISPLATIN VERSUS VINDESINE PLUS CISPLATIN PLUS MITOMYCIN-C IN ADVANCED NON-SMALL-CELL LUNG-CANCER

被引：134
|
作者：
EINHORN, LH
LOEHRER, PJ
WILLIAMS, SD
MEYERS, S
GABRYS, T
NATTAN, SR
WOODBURN, R
DRASGA, R
SONGER, J
FISHER, W
STEPHENS, D
HUI, S
机构：
[1] INDIANA UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,INDIANAPOLIS,IN 46202
[2] PARKVIEW MEM HOSP,FT WAYNE,IN
[3] BULL MEM HOSP,MUNCIE,IN
[4] INDIANA UNIV,DEPT MED,BIOSTAT SECT,INDIANAPOLIS,IN 46204
来源：
JOURNAL OF CLINICAL ONCOLOGY | 1986年 / 4卷 / 07期
关键词：
D O I：
10.1200/JCO.1986.4.7.1037
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1037 / 1043
页数：7
相关论文
共 50 条
  • [41] CISPLATIN VERSUS CISPLATIN PLUS ETOPOSIDE IN THE TREATMENT OF ADVANCED NON SMALL-CELL LUNG-CANCER
    KLASTERSKY, J
    SCULIER, JP
    BUREAU, G
    LIBERT, P
    RAVEZ, P
    VANDERMOTEN, G
    THIRIAUX, J
    LECOMTE, J
    CORDIER, R
    DABOUIS, G
    BROHEE, D
    THEMELIN, L
    MOMMEN, P
    JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (08) : 1087 - 1092
  • [42] Phase II trial of dose intensification with cisplatin and carboplatin plus vindesine in patients with inoperable non-small cell lung cancer
    Nakanishi, Y
    Takayama, K
    Kawasaki, M
    Yatsunami, J
    Inutsuka, S
    Wakamatsu, K
    Tsuruta, N
    Hara, N
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1997, 20 (04): : 393 - 397
  • [43] VINDESINE AND CISPLATIN COMBINATION CHEMOTHERAPY COMPARED WITH VINDESINE AS A SINGLE AGENT IN THE MANAGEMENT OF NON-SMALL CELL LUNG-CANCER - A RANDOMIZED STUDY
    ELLIOTT, JA
    AHMEDZAI, S
    HOLE, D
    DORWARD, AJ
    STEVENSON, RD
    KAYE, SB
    BANHAM, SW
    STACK, BHR
    CALMAN, KC
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1984, 20 (08): : 1025 - 1032
  • [44] MITOMYCIN-C IFOSFAMIDE VS MITOMYCIN-C VINDESINE VS CISPLATINUM ETOPOSIDE IN ADVANCED NON-SMALL CELL LUNG-CANCER - A PROSPECTIVE RANDOMIZED TRIAL
    GATZEMEIER, U
    HECKMAYR, M
    HOSSFELD, DK
    KAUKEL, E
    KOSCHEL, G
    NEUHAUSS, R
    IFOSFAMIDE IN THE TREATMENT OF LUNG CANCER, 1989, 35 : 108 - 118
  • [45] INFLUENCE OF PRETREATMENT CLINICAL CHARACTERISTICS ON THE RESPONSE RATE TO MITOMYCIN VINDESINE CISPLATIN (MVP) IN UNRESECTABLE NON-SMALL-CELL LUNG-CANCER
    RIGGI, M
    RUFFIE, P
    VOISIN, S
    MONNET, I
    DECREMOUX, H
    SALTIEL, JC
    MARTIN, M
    VERGNE, L
    HUET, J
    CVITKOVIC, E
    EUROPEAN JOURNAL OF CANCER, 1991, 27 (10) : 1238 - 1242
  • [46] CISPLATIN, IFOSFAMIDE AND VINDESINE IN THE CHEMOTHERAPY OF NON-SMALL-CELL LUNG-CANCER - A COMBINATION PHASE-II STUDY
    HONDA, R
    FUJITA, A
    INOUE, Y
    ASAKAWA, M
    SUZUKI, A
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 26 (05) : 373 - 376
  • [47] CISPLATIN, VINDESINE AND BLEOMYCIN (CVB) COMBINATION CHEMOTHERAPY OF ADVANCED NON-SMALL CELL LUNG-CANCER
    ITRI, LM
    GRALLA, RJ
    KELSEN, DP
    CHAPMAN, RA
    CASPER, ES
    BRAUN, DW
    HOWARD, JE
    GOLBEY, R
    HEELAN, RT
    CANCER, 1983, 51 (06) : 1050 - 1055
  • [48] THE USE OF GRANULOCYTE COLONY-STIMULATING FACTOR TO SHORTEN THE INTERVAL BETWEEN CYCLES OF MITOMYCIN-C, VINDESINE, AND CISPLATIN CHEMOTHERAPY IN NON-SMALL-CELL LUNG-CANCER
    TAKADA, M
    FUKUOKA, M
    ARIYOSHI, Y
    FURUSE, K
    NIITANI, H
    OTA, K
    MOTOMIYA, M
    HASEGAWA, K
    TOMINAGA, K
    KURIYAMA, T
    YOSHIDA, K
    KIMURA, H
    KURITA, Y
    NAKAJIMA, S
    NAKAI, J
    OHTA, M
    YAMAMOTO, H
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 31 (03) : 182 - 186
  • [49] A phase II study of mitomycin C, vindesine and cisplatin combined with alpha interferon in advanced non-small cell lung cancer
    Silva, RR
    Bascioni, R
    Rossini, S
    Zuccatosta, L
    Mattioli, R
    Pilone, A
    Delprete, S
    Battelli, N
    Gasparini, S
    Battelli, T
    TUMORI, 1996, 82 (01) : 68 - 71
  • [50] A RANDOMIZED TRIAL COMPARING VINDESINE VDS WITH VINDESINE PLUS CIS-PLATINUM (DDP) IN INOPERABLE NON-SMALL CELL LUNG-CANCER (NSCLC)
    ELLIOTT, JA
    AHMEDZAI, S
    STEVENSON, RD
    DORWARD, AJ
    CALMAN, KC
    BRITISH JOURNAL OF CANCER, 1982, 46 (03) : 485 - 486
12345